Helix Therapeutics Expands GMP Manufacturing Capacity with New Large-Scale SPPS Reactor
Boston, MA — March 12, 2025. Helix Therapeutics today announced the successful installation and qualification of a new large-scale automated solid-phase peptide synthesis (SPPS) reactor at its Boston Science Park facility. The addition of this instrument — a custom-configured parallel batch synthesiser capable of 10-kilogram-scale GMP production runs — increases the company's total GMP manufacturing capacity by approximately 300%.
The expansion comes in direct response to surging global demand for clinical-grade peptide active pharmaceutical ingredients (APIs), particularly GLP-1 receptor agonists such as semaglutide, tirzepatide-related sequences, and novel obesity and metabolic disease candidates currently in Phase II and Phase III clinical trials.
A Strategic Response to Market Demand
"The peptide therapeutics market is growing faster than we've ever seen," said Dr. Elena Vasquez, Chief Scientific Officer and Co-founder of Helix Therapeutics. "The success of GLP-1 drugs has demonstrated to the entire pharmaceutical industry that peptides can be blockbuster medicines. We're seeing a wave of new programmes entering clinical development, and companies need reliable, high-quality GMP supply chains they can trust."
Prior to this expansion, Helix operated four GMP synthesis suites capable of batch sizes up to 2 kg per run. The new reactor adds a dedicated fifth GMP suite with a reactor volume supporting single-batch peptide API production of up to 10 kg — sufficient to supply Phase III clinical trials and early commercial launch quantities for most peptide drugs.
Technical Specifications and Validation
The new system has undergone full Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) under the oversight of Helix's Quality Assurance team, in full compliance with ICH Q7 GMP guidelines for active pharmaceutical ingredients. Three performance qualification runs using a model peptide (a 31-amino acid GLP-1 analogue) demonstrated batch-to-batch consistency with HPLC purity ≥98.2% and peptide content ≥85% across all runs.
"The qualification data exceeded our expectations," noted Dr. Priya Nair, Director of Quality Assurance at Helix. "We're particularly pleased with the reproducibility data — coefficients of variation for key quality attributes were all below 2%, which speaks to the robustness of our synthesis protocols at this new scale."
Timeline for Full Operation
The new GMP suite is now accepting project requests. Helix estimates that the expanded capacity will allow the company to serve three to four additional long-term clinical supply customers simultaneously, in addition to its existing client base. The company anticipates accepting its first multi-year clinical supply agreement under the expanded capacity in Q2 2025.
Pharmaceutical companies and biotechs with GLP-1 programme needs or other clinical-stage peptide requirements are encouraged to contact the Helix GMP team directly at gmp@helixtherapeutics.com.
About Helix Therapeutics
Helix Therapeutics is a leading peptide synthesis company headquartered in Boston, MA. Founded in 2009, Helix specialises in custom and catalog peptide synthesis for pharmaceutical, research, and cosmetic applications. The company operates ISO 9001:2015-certified and GMP-compliant manufacturing facilities, serving clients in over 40 countries.